drugset / Trial / NCT01613495
Ghrelin Suppression by Octreotide in Prader-Willi
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to learn more about how octreotide (Sandostatin LAR® Depot) affects levels of ghrelin, hunger, and body weight in people with Prader-Willi Syndrome.
Timeline
- Start
- 2005-08
- Primary completion
- 2024-03
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Octreotide | Peptide | — | — |